Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

    ... due to intense intravascular hemolysis . Eculizumab , a monoclonal antibody against the complement protein ... in PNH. We evaluated 79 consecutive patients treated with eculizumab in Leeds between May 2002 and July 2010. Mortality and disease ...

    Research Article last updated 10/11/2011 - 5:58pm.

  2. Successful pregnancy outcome in paroxysmal nocturnal hemoglobinuria (PNH) following escalated eculizumab dosing to control breakthrough hemolysis

    ... syndrome and PNH. After two years of treatment with eculizumab , she became pregnant. She developed breakthrough hemolysis ... and pharmacodynamic studies demonstrated a subtherapeutic eculizumab level with absence of complement blockade. Escalation of her ...

    Research Article last updated 06/23/2015 - 9:29am.

  3. Chronic treatment of paroxysmal nocturnal hemoglobinuria patients with eculizumab: safety, efficacy, and unexpected laboratory phenomena

    ... The terminal complement inhibitor eculizumab has become the standard of treatment in patients with ... study, 19 PNH patients received chronic therapy with eculizumab with a median duration of 16 months (range 6-46 months). Parameters ...

    Research Article last updated 10/11/2011 - 5:58pm.

  4. Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria

    Journal Title:  Int J Hematol Primary Author:  Iki S Author(s):  Iki S, Ohgi ...

    Research Article last updated 12/09/2016 - 2:06pm.

  5. Predictors of Hemoglobin Response to Eculizumab Therapy in Paroxysmal Nocturnal Hemoglobinuria

    ... anemia and bone marrow failure . Eculizumab has been shown to improve anemia, decrease intravascular ... retrospective, single-center study of patients treated with Eculizumab and categorized according to response criteria. Complete response ...

    Research Article last updated 11/05/2012 - 10:28am.

  6. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab.

    ... before and after five and 11 weeks of treatment with eculizumab . We examined markers of thrombin generation and reactional ... with no history of clinical thrombosis. Treatment with eculizumab was associated with significant decreases in plasma markers ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria

    ... with reduced survival. The terminal complement inhibitor eculizumab is proven to be effective and safe in adults and approved by the ... and safety in seven children with PNH 11-17 years of age. Eculizumab was intravenously administered at 600 mg weekly for 4 weeks, ...

    Research Article last updated 05/22/2014 - 8:29am.

  8. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.

    ... the safety and efficacy of the complement inhibitor eculizumab in altering its progression. Renal dysfunction or damage was ... rate [GFR] <or=60 ml/min/1.73 m(2); Stage 3, 4, or 5). Eculizumab treatment was safe and well-tolerated in patients with renal ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Successful Use of Eculizumab in a Pediatric Patient Treated for Paroxysmal Nocturnal Hemoglobinuria

    ... in adulthood and are very rarely reported in children. Eculizumab , a humanized monoclonal antibody targeting and ... disease-related complications in patients with PNH. Although eculizumab is not licensed for use in pediatrics, we report a young PNH patient ...

    Research Article last updated 07/31/2012 - 12:38pm.

  10. Improving cytopenia with splenic artery embolization in a patient with paroxysmal nocturnal hemoglobinuria on eculizumab

    ... under treatment with the anti-complement antibody eculizumab who developed pancytopenia , requiring blood ...

    Research Article last updated 01/08/2014 - 9:53am.